Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Debt Investor Presentation (August 2026)
36 slides from Fresenius SE & Co. KGaA's debt investor presentation, August 2026
Slide 1: Credit Presentation Q2 2026
Credit Presentation Q2 2026 © Fresenius 2026 | Credit Presentation
Slide 2: Safe harbor statement and Glossary
Safe harbor Glossary statement This presentation contains forward-looking statements that are subject to cc At constant currency various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, Core EPS Earnings
Slide 3: Company overview
01 Company overview 02 Strategy Business Update 03 Financials 04 Credit highlights 05 #Future Fresenius 06 Appendix 01 02 03 04 05 06 Company Strategy & Financials Credit #Future Appendix overview Business highlights Fresenius Update 3 © Fresenius 2026 | Credit Presentation
Slide 4: Fresenius now simpler, stronger and more focused
Fresenius group now simpler, stronger and more focused Fresenius Kabi Fresenius Helios Products for critically and chronically ill patients Europe’s leading private healthcare provider Pharma Biopharma Nutrition MedTech 4 © Fresenius 2026 | Credit Presentation
Slide 5: Fresenius Kabi: Strong relevance and scale across 4 business units
Fresenius Kabi Strong relevance and scale across 4 business units BASE BUSINESS GROWTH VECTORS Pharma Nutrition MedTech Biopharma Hospital-sold generic IV Drugs Enteral and Parenteral Stationary drug delivery AIID & oncology biologic drugs and Fluids Nutrition products and therapy devices (biosimila
Slide 6: Fresenius Helios: #1 hospital provider in Europe
Fresenius Helios #1 hospital provider in Europe with superior medical quality Germany Spain1 80+ hospitals 31 ORP 57 hospitals 300+ ORP centers centers Overview Largest 200+ outpatient 6 prevention 120+ outpatient hospital lab centers centers centers in Spain #1 hospital provider across all operator
Slide 7: Strategy & Business Update
01 Company overview 02 Strategy Business Update 03 Financials 04 Credit highlights 05 #Future Fresenius 06 Appendix 01 02 03 04 05 06 Company Strategy & Financials Credit #Future Appendix overview Business highlights Fresenius Update 7 © Fresenius 2026 | Credit Presentation
Slide 8: Q2/26: Strong execution delivers highest returns in the decade
Q2/26: Strong execution delivers highest returns in the decade Excellent EPS Sustainable Leverage at Fresenius Fresenius FY/26 growth: value creation: lower end of Kabi: Helios: Guidance target corridor: Based on continued ROIC improved by Increased strategic #FutureFresenius an Strong and resilient
Slide 9: Fresenius Kabi: Q2/26 news
Fresenius Kabi: Q2/26 news Pharma Biopharma Nutrition MedTech Pipeline enhancement vedolizumab European launch of Strong execution of with 7 new in- biosimilar candidate Pedismof® range, a Ivenix U.S. licensing deals added for IV treatment new ready to use three installations including by end of Q2/
Slide 10: Fresenius Kabi: Biopharma growth engine
Fresenius Kabi: Biopharma growth engine tocilizumab | autoimmune ustekinumab | autoimmune denosumab | osteoporosis & oncology EU launch: Nov 2023 EU launch: Mar 2025 US launch: Jul 2025 US launch: Apr 2024 (IV), Jul 2024 (SC) US launch: Mar 2025 EU launch: Dec 2025 44% EU4+UK market share 18 markets
Slide 11: Fresenius Helios: Q2/26 news
Fresenius Helios: Q2/26 news Germany Spain GKV Stabilization Act Annual Research Day at approved – providing a Quirónsalud – almost 1,500 constructive framework for active clinical trials reached in continued reimbursement 2025 (+2% yoy), and 410 growth newly initiated trials 15 years of ERACS study
Slide 12: Committed to Helios 10-12% structural margin band
Committed to Fresenius Helios’ 10 – 12% structural margin band, FY/27 EBIT growth expected Fresenius Helios Strategic Indicative EBIT1 development drivers Germany • Leverage hospital network • Process optimization & utilization • Accelerate cost & incl. efficiency measures GKV Act incl. • Mid-term G
Slide 13: Raising Core EPS guidance
Raising Core EPS guidance Organic revenue Core EPS growth growth cc 4 – 7% 10 – 15% Previously: 5 – 10% Before special items Guidance assumes current factors and known uncertainties but does not reflect potential extreme scenarios from a fast-moving geopolitical environment. 13 © Fresenius 2026 | Cr
Slide 14: Financials
01 Company overview 02 Strategy Business Update 03 Financials 04 Credit highlights 05 #Future Fresenius 06 Appendix 01 02 03 04 05 06 Company Strategy & Financials Credit #Future Appendix overview Business highlights Fresenius Update 14 © Fresenius 2026 | Credit Presentation
Slide 15: Q2/26: Converting operational momentum into earnings strength
Q2/26: Converting operational momentum into earnings strength Revenue EBIT EBIT Strong organic revenue growth in line with expected FY/26 phasing margin Excellent EBIT margin at 12.3%; +60bps YOY driven by both Fresenius Kabi and Fresenius Helios €5.9bn €719m 12.3% Outstanding Core EPS growth of 14%
Slide 16: Fresenius Kabi Q2/26 financials
Fresenius Kabi Q2/26 financials Strong organic revenue growth of 7%1, at the upper end of the structural growth band (4 – 7%) 16.7% 16.7% 17.0% EBIT • Growth Vectors with excellent 12%1 organic revenue growth 16.4% 15.8% margin (Biopharma: 38%1; MedTech: 11%1; Nutrition: 5%1) • Pharma with organic r
Slide 17: Fresenius Helios Q2/26 financials
Fresenius Helios Q2/26 financials Strong organic revenue growth of 5%, in line with structural growth band (4 – 6%) 11.7% 10.5% 10.6% EBIT Strong EBIT margin of 10.6 %, well within the structural margin 10.0% margin band (10 – 12%) 8% Helios Germany: 7.5% Organic • Strong 6% organic revenue growth (
Slide 18: Structurally improved Cash Flow
Structurally improved Cash Flow Cash Flow, €m Excellent €2.8bn Operating Cash Flow in Q2/26 LTM: strong 2,819 incl. improvement through proceeds from pro- disciplined cash rata FME management -825 share sales Successful cash conversion: -619 286 -199 1,592 Q2/26 LTM CCR2: 1.2 130 FY/25 CCR2: 1.1 999
Slide 19: Raising Core EPS guidance based on strong operational results
Raising Core EPS guidance based on strong operational results Indications Organic revenue Core EPS Fresenius Group EBIT margin of around 11.5% growth growth cc FY/25 base: €2,595m 4 – 7% 10 – 15% Fresenius Kabi Mid- to high-single-digit org. revenue growth Previously: 5 – 10% FY/25 base: €8,612m EBI
Slide 20: Fresenius Financial Framework
Fresenius Group Fresenius Financial Framework Fresenius Fresenius Ambitions geared Kabi Helios for substantial earnings growth EBIT margin 17 – 19% 10 – 12% Strong balance across Organic revenue growth and stable cash growth 4 – 7% 4 – 6% flow Capital Efficiency Capital Structure Cash Committed to s
Slide 21: Credit highlights
01 Company overview 02 Strategy Business Update 03 Financials 04 Credit highlights 05 #Future Fresenius 06 Appendix 01 02 03 04 05 06 Company Strategy & Financials Credit #Future Appendix overview Business highlights Fresenius Update 21 © Fresenius 2026 | Credit Presentation
Slide 22: Structural step-up in our financial metrics
Structural step-up in our financial metrics ~5.5% 2.5 – 3.0× Strong returns for CAPEX as % of revenue Leverage (Net debt/EBITDA) shareholders while investing expected in FY/26 target corridor in future growth We do not compromise on We are committed to a disciplined capital strong balance sheet allo
Slide 23: Prudent financing strategy and financial policy
Prudent financing strategy and financial policy Diversified financing mix1 Financial policy highlights • Sufficient liquidity reserve1 : Other financial liabilities 2% Bonds 72% Undrawn ESG-linked revolving credit facility of €2bn EIB Loan 4% Total B/S Committed available bilateral credit facilities
Slide 24: Fresenius SE: Credit rating overview
Fresenius SE: Credit rating overview Rating history Rating agencies’ key statements pos pos “In our view, the group's strengthening business profile BBB stab stab Baa2 underpins the progressive strengthening of the credit neg neg metrics and improved rating trajectory implied by the pos pos positive
Slide 25: Capital efficiency and returns
Fresenius Group Capital efficiency and returns ROIC1, % CCR1,2 Net debt / EBITDA1,3 9.0 1.3 4.0 1.2 1.2 1.2 8.0 1.2 3.5 6.9 1.1 1.1 1.1 3.2 7.0 6.8 1.1 3.1 6.6 3.0 3.0 6.3 6.1 6.2 6.2 6.2 1.0 1.0 3.0 3.0 6.0 1.0 2.7 2.6 2.6 2.5 5.0 0.9 4.0 0.8 2.0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 26: Key Credit KPIs Q2 2026
Key Credit KPIs Q2 2026 Leverage Cash flow Net debt/EBITDA1,2 2.6 x Operating Cash flow3 in % of revenue 5.9% Gross debt/EBITDA1,2 2.9 x Free Cash flow3,4 in % of revenue 4.1% Equity ratio 48.7% Cash Conversion Rate 1.2 Interest coverage Investments EBITDA/Interest1,5 13.7 x Capex in % of revenue 3.
Slide 27: #FutureFresenius
01 Company overview 02 Strategy Business Update 03 Financials 04 Credit highlights 05 #Future Fresenius 06 Appendix 01 02 03 04 05 06 Company Strategy & Financials Credit #Future Appendix overview Business highlights Fresenius Update 27 © Fresenius 2026 | Credit Presentation
Slide 28: REJUVENATE in action
REJUVENATE in action H1/26 FY/251 Structural step-up Seizing opportunities #FutureFresenius translating Leveraging strong EBIT margin into continued earnings strength – as demonstrated operational momentum for innovation-led growth 12.0% 11.5% by Guidance upgrade Core EPS growth cc Strategic flexibi
Slide 29: Reinforcing our ability to win
Reinforcing our ability to win Right to play Ability to win Established healthcare platforms providing long-term structural opportunities Growth Vectors driving topline acceleration and profitability as strategic, innovation-led growth engines 2.6× + Net debt/EBITDA FME stake Biopharma Nutrition Med
Slide 30: Appendix
01 Company overview 02 Strategy Business Update 03 Financials 04 Credit highlights 05 #Future Fresenius 06 Appendix 01 02 03 04 05 06 Company Strategy & Financials Credit #Future Appendix overview Business highlights Fresenius Update 30 © Fresenius 2026 | Credit Presentation
Slide 31: Fresenius Group: Business overview
Fresenius Group: Business overview Fresenius Strong underlying, Driving growth, Fresenius Helios sustained leadership accelerating performance Kabi Germany Spain Pharma Nutrition MedTech Biopharma Leader in Vertically- WHERE WE Clear market Clear market Global IV Gx & Scaled MedTech integrated integ
Slide 32: Fresenius Kabi: Biosimilar portfolio and pipeline
Fresenius Kabi Biosimilar portfolio and pipeline Candidate & TA Pre-clinical Clinical trials Approval Launch Adalimumab EU: Apr 2019 / US: Dec 2022 EU: May 2019 / US: Jul 2023 Autoimmune Pegfilgrastim EU: Mar 2022 / US: Sep 2022 EU PFS: Oct 2022 / US PFS: Feb 2023 Oncology FRESENIUS KABI Tocilizumab
Slide 33: Fresenius Kabi: Biosimilar portfolio and pipeline
Fresenius Kabi Biosimilar portfolio and pipeline Fresenius biosimilar portfolio & pipeline 40 Global peak branded sales of originators1, €b ~90 Fresenius ~40 mAbxience Fresenius and mAbxience ~35 ~210 28 aflibercept 6 rituximab2 7 6 vedolizumab 4 molecules 5 molecules 3 10 nivolumab 21 etanercept 4
Slide 34: Helios Germany: Constructive framework for reimbursement growth
Helios Germany Constructive framework for continued reimbursement growth DRG Inflator Regular support from additional funds Annual price increase for reimbursement of hospital treatments Around 70% of German hospitals are loss-making amid continued cost pressure, requiring additional government supp
Slide 35: Helios Germany: Regulatory changes playing to our strengths
Helios Germany Regulatory changes playing to our strengths Structural hospital reform1 GKV Stabilization Act1,4 Create a more quality-driven and specialized hospital sector Stabilize the statutory health insurance system (GKV) and – in effect since January 2025 with multi-year, phased limit rising c
Slide 36: Financial Calendar & Contact
Financial Calendar & Contact Financial Calendar Please note that these dates could be subject to change. Investor Feedback and Social Media 05 Aug 2026 Q2 2026 results Open dialogues are vital to us! We have teamed up with Quantifire for quick and convenient feedback sharing. You can submit your fee
Fresenius SE & Co. KGaA — Debt Investor Presentation (August 2026) on 6ix